61 results about "Cutaneous tissue" patented technology

A minimally-invasive fluid-cooled insertion sleeve assembly, with an attached balloon and distally-located penetrating tip, into which sleeve any of a group comprising a rigid rod, a microwave-radiator assembly and an ultrasonic-imaging transducer assembly may be inserted, constitutes a probe of the system. The sleeve assembly comprises spaced inner and outer plastic tubes with two fluid channels situated within the coaxial lumen between the inner and outer tubes. The fluid coolant input flows through the fluid channels into the balloon, thereby inflating the balloon, and then exits through that coaxial lumen. An alternative embodiment has no balloon. The method employs the probe for piercing sub-cutaneous tissue and then ablating deep-seated tumor tissue with microwave-radiation generated heat.

Embodiments of the invention relate to a composition, a process of making the composition, and to the use of the composition. The compositions include a molecular complex formed between an alkaline pharmaceutical drug and at least one selected from a hydroxyacid, a polyhydroxy acid, a related acid, a lactone, or combinations thereof. The compositions provide improved bioavailability and improved delivery of the drug into the cutaneous tissues.

Performing selective photothermolysis of sub-cutaneous tissue by using a plurality of beams of narrow band electro-magnetic radiation, where each of the beams have energy that is insufficient to heat the tissue that they strike to a temperature high enough to destroy such tissue, but by directing the individual beams to overlap at the target sufficient heat is generated to destroy the target tissue.

Embodiments of the invention relate to a composition, a process of making the composition, and to the use of the composition. The compositions include a molecular complex formed between an alkaline pharmaceutical drug and at least one selected from a hydroxyacid, a polyhydroxy acid, a related acid, a lactone, or combinations thereof. The compositions provide improved bioavailability and improved delivery of the drug into the cutaneous tissues.

A method and an apparatus for measuring glucose level in the body fluid of a subject, typically blood glucose level, by measuring impedance of a body tissue, with two pairs of electrodes, two electrodes for injecting current into a body tissue and two electrodes for detecting the ensuing voltage of the body tissue. The body tissue is typically a sub-dermal or sub-cutaneous tissue. The measured impedance of the body tissue is used to correlate with directly determined glucose levels to determine the glucose level from the measured impedance. It is thus possible to determine body fluid glucose levels in a reliable and reproducible manner.

The invention relates to a device for carrying out the nondestructive optical constant imaging of a human body cutis pathologic tissue and a method thereof. The device comprises a tungsten halogen lamp, an incident fiber optic probe, a line array CCD for receiving diffused reflection light, and a grating spectrograph, an amplification filter circuit, an A/D conversion circuit, a computer and a computer-controlled three-dimensional traveling table which are connected in turn through an optical fiber. The invention uses the line array CCD optical measurement device detecting the obliquely incident diffused reflection light to detect the human body cutis tissue, uses a Monte Carlo statistical method limited by characteristic parameters to conversely compute the values of the absorption coefficient and the reduction scattering coefficient at each two-dimensional space coordinates of the detected cutis tissue, then uses the grating spectrograph to carry out spectrum, and respectively images through the absorption coefficient and the reduction scattering coefficient and simultaneously detects the detected human body pathologic tissue and a healthful tissue around the pathologic tissue. Then the optical constants of the pathologic tissue and the healthful tissue are compared to see difference or the optical constant of the pathologic tissue is compared with a healthful human body tissue sample, thereby carrying out the diagnosis and identification of diseases.

The invention relates to the use of a Rhodiola crenulata extract, via the topical route, for increasing the energy metabolism of the cutaneous tissues of a subject.

The invention relates notably to topical compositions which comprise an active agent for increasing the energy metabolism of the cutaneous tissues of a subject, said active agent being a Rhodiola crenulata extract. The present invention enables making a cosmetic care such as fighting against, or slowing down or preventing the loosening of the cutaneous tissue, increasing the plasticity of the cutaneous tissue, exerting an anti-wrinkle effect or slowing down or preventing the appearance of wrinkles, fighting against, slowing down or preventing the appearance of acne, exerting a depigmenting effect of the cutaneous tissue, in particular of the skin, and promoting desquamation of the cutaneous tissue (or “peeling”).

The present invention relates to a microscopic-spots irradiating device applying a vacuum thereof that is provided with a laser beam or flash-lamp light-generating device, a multiple microscopic-spot generating device that creates multiple microscopic spots in cutaneous tissues, and a suction device that sucks up cutaneous tissues during the illumination thereof by the laser beam or flash lamp. The irradiating device of the present invention performs a laser treatment by forming a large number of microscopic spots in subcutaneous tissues that have been pulled up and stretched by suction, making it possible to encourage the treatment of pigmented lesions and regenerate new skin, while minimizing post-inflammatory or post-operative hyperpigmentation.

The present invention is a method for cutting a fowl to create a meat cut which includes the radius bone and muscles (meat) adhering to the radius bone. The method involves separating the radius bone and muscles adhering to the radius bone from the carcass of the fowl, and then removing the radius bone and muscles adhering to the radius bone from the carcass of the fowl. The meat cut may be produced with the cutaneous tissues attached to the muscles adhering to the radius bone or with the cutaneous tissues removed from the muscles adhering to the radius bone to produce a skinless meat cut. The resulting meat cut contains a larger percentage of meat and is easier to consume. Alternatively, a portion of the muscles (meat) adhering to the radius bone can be removed to create a meat cut having less meat.

Pharmacological test shows that the externally-used preparation of Cetirizine has ideal allergy resistant and anti-inflammatory action to the rat passive cutaneous anaphylaxis (Rat PCA) model and dimethylbenzene caused mouse otitis model, and also prevents the adverse effect to the central system caused by whole body administration. It is also found in the test, that the externally used preparation of Cetirizine also has very fine inhibitory action to dinitrofluorobenzene caused mouse porphyria hypersensitivity (PTH), the novel pharmacological action of the Cetirizine shows that the Cetirizine external preparation has good therapeutic action to skin inflammations which mainly include porphyria hypersensitivity.

The present invention includes a growth factor profile, connective tissue matrix constituents, and immunoprivileged status of equine placental tissue extracellular matrix (ECM) and accompanying cutaneous tissue, plus the presence of antimicrobial peptides there, render equine placental tissue an ideal source for biological scaffolds for xenotransplantation, and optionally adding at least one of: one or more block-copolymers, one or more osteogenic agent or one or more osteoinductive agents.

The present invention identifies genes whose gene products are differentially expressed lymphedema tissues, particularly cutaneous tissue involved in whole organ response to lymphedema. The invention provides methods for diagnosing or assessing an individual's susceptibility to lymphedema. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lymphedema. Additionally, the invention describes screening methods for identifying agents that can be administered to treat individuals that have or at risk of developing lymphedema.

The invention belongs to the field of biomedical polymer materials, and discloses a micro-needle array patch capable of generating gas to take effect quickly and preparation and application thereof. The micro-needle array patch comprises a substrate and a needle tip located on the substrate, the substrate is composed of a biocompatible matrix, the needle tip is mainly composed of the biocompatible matrix and inorganic particles capable of generating gas, and the inorganic particles capable of generating gas are formed on the surface and/or in the biocompatible matrix of the needle tip; the needle tip part of the micro-needle array patch can interact with skin tissue fluid to generate gas during application, rapid dissolution of micro-needles and diffusion of drugs to a corium layer are promoted, and the drugs can be efficiently and rapidly delivered to subcutaneous parts and take effect without the help of external equipment.

The present invention identifies genes whose gene products are differentially expressed in lymphedema tissues, particularly cutaneous tissue involved in whole organ response to lymphedema. The invention provides methods for diagnosing or assessing an individual's susceptibility to lymphedema. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lymphedema. Additionally, the invention describes screening methods for identifying agents that can be administered to treat individuals that have or at risk of developing lymphedema.

The invention discloses a human skin tissue endogenous polypeptide PDHPS1 and an application thereof. The amino acid sequence of the human skin tissue endogenous polypeptide PDHPS1 is shown in SEQ IDNO.1. The polypeptide PDHPS1 inhibits the propagation of a scar dermal fibroblast, inhibits the expression of mRNA of collagen genes COL1A1 and COL1A2 in the scar dermal fibroblast, and obviously reduces the protein expression of a main marker alpha-SMA of a myofibroblast in the scar dermal fibroblast. The human skin tissue endogenous polypeptide PDHPS1 can be used to prepare a drug or agent whichcan inhibit the propagation of the scar dermal fibroblast, reduce the collagen content and reduce the amount of the myofibroblast, and provides a new target spot for inhibiting the scar hypertrophy.

A method and apparatus for preparing tissue specimens for histological study utilizing two connectable sections each with hollowed cylinders for receiving first and second buttons, each button including planar disc and cylindrical stem portions, such that the stem portions can be slideably mounted in hollowed cylinders. The planar disc portions of the buttons are capable of receiving tissue specimens.

The invention discloses a functional gel layer, a scar patch and a preparation method of the scar patch, and relates to the technical field of medical supplies. The functional gel layer comprises the following components in parts by weight: 2-30 parts of a protein repairing agent, 0.5-10 parts of sodium hyaluronate and the balance of purified water, and the sum of the parts by weight of the components is 100; the protein repairing agent is selected from at least one of collagen and mussel mucin. The scar patch disclosed by the invention can be directly applied to non-closed wounds, and can be used for inhibiting scar formation, reducing the itching degree, promoting wound healing and accelerating functional recovery of skin tissues.

A novel method for the prophylactic or therapeutic treatment of skin disorders and diseases by the application of a medicament that includes at least one cyanoacrylate compound. The medicament offers an advantageously novel alternative to hitherto known medicaments for the treatment of exanthemas, psoriasis exanthemas, and exanthemas in connection with fungal infections, as well as virus infections, and revision of infected and non-infected wounds.